Cancer Statistics Public Use Databases. Minus Related Pages. Documentation for U. Data — Skip directly to site content Skip directly to page options Skip directly to A-Z link. Section Navigation. Facebook Twitter LinkedIn Syndicate. About U. Cancer Statistics. Minus Related Pages. Cancer Statistics Home. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately SEER coverage includes The SEER Program registries routinely collect data on patient demographics, primary tumor site, tumor morphology and stage at diagnosis, first course of treatment, and follow-up for vital status.
The SEER Program is the only comprehensive source of population-based information in the United States that includes stage of cancer at the time of diagnosis and patient survival data. The population data used in calculating cancer rates is obtained periodically from the Census Bureau.
The abdomen was the most common primary site Most cases were detected in later treatment eras, perhaps because of the expanding coverage of the SEER registry. Overall, the IR of neuroblastoma has remained stable at 0.
Moreover, the rate in children was on the rise as a whole, from 0. Evolution of the incidence rates of neuroblastoma by period and age group in the Surveillance, Epidemiology and End Results Program database from to Final Selected Model: 0 Joinpoints. Overall, the prognosis of neuroblastoma patients has greatly improved in recent years Figure 3A, 3G. Additionally, male patients had worse long-term survival than female patients Figure 3E, 3K. The 5- and year OS rates were Kaplan-Meier curves of overall survival for all patients, stratified by age at diagnosis A , and the 5- and year survival probabilities by age group B.
Multivariate Cox proportional hazards regression analyses evaluating factors influencing overall survival in patients with neuroblastoma. This study was conducted to compare the IR of neuroblastoma and survival outcomes in children, adolescents, and adults using the SEER program database.
In the past 40 years, the incidence of neuroblastoma in the general population has been relatively stable, maintaining at around 0. Moreover, some prognostic factors for OS in different populations were identified. In the study conducted by Tas et al.
In our study, the APC for childhood patients from to was 0. Georgakis et al. Moreover, close monitoring of IR and mortality are needed to avoid unnecessary treatment while ensuring the best possible outcome for patients. Esiashvili et al. They found that there was a steady decline in the IR of neuroblastoma in adults 20 years or older from — to — Similar conclusions were drawn in the study of Ries et al.
In our study, in the past 40 years, the incidence of adult neuroblastoma has shown a significant downward trend with an APC value of statistical significance. In this study, in terms of survival, the OS and CSS rates of patients diagnosed in recent years were better than those diagnosed many years ago. Panagopoulou et al. We attribute the improved survival outcomes to the advanced methods of treatment, including targeted therapy [ 25 ] and immunotherapy [ 26 ].
Ali et al. Additionally, Esiashvili et al. Lu et al. The disease itself tends to spontaneously regress in pediatric patients, especially in infants, and is more likely to have metastatic status in adult patients. Generally, primary site, surgery, sequence of primary malignancy, stage, and treatment era were recognized as prognostic factors in all age groups.
However, gene-related prognostic factors were not included in our study due to the limitations of the database itself. In previous studies, many genes have been recognized to be associated with the progression and prognosis of neuroblastoma. The oncogenic role of the anaplastic lymphoma receptor tyrosine kinase ALK gene has already been reported because of the high protein expression levels [ 29 ]. In addition, many other genes have been shown to be associated with adverse outcomes [ 2 ].
The present study has certain limitations that should be considered. This is a U. In addition, there may be inaccuracies in data collection for any registry. Co-morbidities and preventive treatments are not included in SEER. Because data on tumor recurrence are not currently collected, progression-free survival PFS and the outcome from salvage therapies cannot be assessed. Survival outcome data may be affected by curative and palliative therapy, duration of chemotherapy, and the use of other treatments, and these were not considered in the database.
0コメント